Bellicum Pharmaceuticals Enters into Research Collaboration with Leiden University Medical Center to Discover Natural High-Affinity TCRs
New collaboration builds on current license and research agreement for TCR candidates, including BPX-701
Clinical stage biopharmaceutical company Bellicum Pharmaceuticals, Inc. focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, has entered into a research agreement with Leiden University Medical Center (LUMC) to discover and validate natural high-affinity TCR (T cell receptor) product candidates targeting several cancers. The new collaboration builds on an earlier agreement with LUMC that gave Bellicum worldwide rights to TCR product candidates targeting solid tumors that express PRAME (preferentially-expressed antigen in melanoma) and other antigens.
Kite Pharma and Leiden University Medical Center Sign Research and License Agreement for T Cell Receptors Targeting HPV-Associated Cancers
(January 13, 3016)
Th European subsidiary of Kite Pharma, Inc. has entered into a research and license agreement with Leiden University Medical Center (LUMC) to identify and develop T cell receptor (TCR) product candidates targeting solid tumors that are associated with the human papillomavirus (HPV) type 16 infection.
Bellicum Pharmaceuticals Licenses TCR Technology From Leiden University Medical Center
- Lead TCR candidate targeting solid tumors to begin clinical studies in 2015
(April 29, 2015)
Clinical stage biopharmaceutical company Bellicum Pharmaceuticals, Inc. focused on discovering and developing novel cellular immunotherapies, has entered into a license agreement with Leiden University Medical Center (LUMC) for worldwide rights to develop, manufacture and commercialize high-affinity TCR (T cell receptor) product candidates targeting solid tumors expressing the preferentially-expressed antigen in melanoma, or PRAME.
As small as a salt crystal: portrait of King Willem-Alexander for major of Leiden
(April 23, 2015)
Leiden - Willem te Beest, vice-president of Leiden University and president of the Leiden Bio Science Park foundation, will present a micro-3D-portrait of King Willem-Alexander to the mayor of Leiden Henri Lenferink on King's Day. This portrait of the King is as small as a salt crystal. It has been produced with a printer developed by Idris Solutions, the Leiden company of student entrepreneurs Hans-Peter Mulder and Peter Wiegman.